» Articles » PMID: 37394976

Effects of Social Determinants of Health on Mortality and Incident Liver-related Events and Cardiovascular Disease in Steatotic Liver Disease

Overview
Date 2023 Jul 3
PMID 37394976
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Social determinants of health (SDOH) are becoming increasingly recognised as mediators of human health. In the setting of metabolic dysfunction-associated steatotic liver disease (MASLD), most of the literature on SDOH relates to individual-level risk factors. However, there are very limited data on neighbourhood-level SDOH in MASLD.

Aim: To assess whether SDOH impact fibrosis progression in patients who already have MASLD.

Methods: This was a retrospective cohort study of patients with MASLD seen at Michigan Medicine. The primary predictors were two neighbourhood-level SDOH, 'disadvantage' and 'affluence'. The primary outcomes were mortality, incident liver-related events (LREs) and incident cardiovascular disease (CVD). We modelled these outcomes using Kaplan-Meier statistics for mortality and competing risk analyses for LREs and CVD, using a 1-year landmark.

Results: We included 15,904 patients with MASLD with median follow-up of 63 months. Higher affluence was associated with lower risk of overall mortality (hazard ratio 0.49 [0.37-0.66], p < 0.0001 for higher vs. lower quartile), LREs (subhazard ratio 0.60 [0.39-0.91], p = 0.02) and CVD (subhazard ratio 0.71 [0.57-0.88], p = 0.0018). Disadvantage was associated with higher mortality (hazard ratio 2.08 [95% confidence interval 1.54-2.81], p < 0.0001 for the highest vs. lowest quartile) and incident CVD (subhazard ratio 1.36 [95% confidence interval 1.10-1.68], p < 0.0001). These findings were robust across several sensitivity analyses.

Discussion: Neighbourhood-level SDOH are associated with mortality, incidence of LREs and incident CVD in patients with steatotic liver disease. Interventions aimed at disadvantaged neighbourhoods may improve clinical outcomes.

Citing Articles

Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD.

Czapla B, Dalvi A, Hu J, Moran I, Wijarnpreecha K, Chen V Sci Rep. 2025; 15(1):7976.

PMID: 40055450 PMC: 11889092. DOI: 10.1038/s41598-025-93082-6.


Outcomes in Acute Decompensated Congestive Heart Failure Admissions with Chronic Liver Disease: A Nationwide Analysis Using the National Inpatient Sample.

Varughese V, Nagesh V, Moliya P, Gonzalez N, Martinez E, Mujadzic H Med Sci (Basel). 2025; 13(1).

PMID: 39982244 PMC: 11843908. DOI: 10.3390/medsci13010019.


Population screening for cirrhosis.

Thiele M, Pose E, Juanola A, Mellinger J, Gines P Hepatol Commun. 2024; 8(9).

PMID: 39185917 PMC: 11357699. DOI: 10.1097/HC9.0000000000000512.


Food inequity and insecurity and MASLD: burden, challenges, and interventions.

Zelber-Sagi S, Carrieri P, Pericas J, Ivancovsky-Wajcman D, Younossi Z, Lazarus J Nat Rev Gastroenterol Hepatol. 2024; 21(10):668-686.

PMID: 39075288 DOI: 10.1038/s41575-024-00959-4.


Envisioning how to advance the MASH field.

Allen A, Younossi Z, Diehl A, Charlton M, Lazarus J Nat Rev Gastroenterol Hepatol. 2024; 21(10):726-738.

PMID: 38834817 DOI: 10.1038/s41575-024-00938-9.


References
1.
Leache L, Gutierrez-Valencia M, Saiz L, Uriz J, Bolado F, Garcia-Erce J . Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis. Aliment Pharmacol Ther. 2022; 57(6):620-634. DOI: 10.1111/apt.17344. View

2.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

3.
Kanwal F, Shubrook J, Adams L, Pfotenhauer K, Wong V, Wright E . Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021; 161(5):1657-1669. PMC: 8819923. DOI: 10.1053/j.gastro.2021.07.049. View

4.
Christine P, Young R, Adar S, Bertoni A, Heisler M, Carnethon M . Individual- and Area-Level SES in Diabetes Risk Prediction: The Multi-Ethnic Study of Atherosclerosis. Am J Prev Med. 2017; 53(2):201-209. PMC: 5584566. DOI: 10.1016/j.amepre.2017.04.019. View

5.
Ng C, Lim W, Lim G, Tan D, Syn N, Muthiah M . Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022; 21(4):931-939.e5. PMC: 10792524. DOI: 10.1016/j.cgh.2022.04.014. View